Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul;6(4):226-235.
doi: 10.1159/000505295. Epub 2020 Mar 26.

Application of Histone Deacetylase Inhibitors in Renal Interstitial Fibrosis

Ling Nie  1 , Yong Liu  1 , Bo Zhang  1 , Jinghong Zhao  1
Affiliations
Review

Application of Histone Deacetylase Inhibitors in Renal Interstitial Fibrosis

Ling Nie et al. Kidney Dis (Basel). 2020 Jul.

Abstract

Background: Renal interstitial fibrosis is characterized by the accumulation of extracellular matrix proteins, which is a common feature of chronic kidney diseases.

Summary: Increasing evidence has shown the aberrant expression of histone deacetylases (HDACs) in the development and progression of renal fibrosis, suggesting the possibility of utilizing HDAC inhibitor (HDACi) as therapeutics for renal fibrosis. Recent studies have successfully demonstrated the antifibrotic effects of HDACis in various animal models, which are associated with multiple signaling pathways including TGF-β signaling, EGRF signaling, signal transducer and activator of transcription 3 pathway, and JNK/Notch2 signaling. This review will focus on the utilization of HDACi as antifibrotic agents and its relative molecular mechanisms.

Key messages: HDACis have shown promising results in antifibrotic therapy, and it is rational to anticipate that HDACis will improve clinical outcomes of renal fibrosis in the future.

Keywords: Histone deacetylases; Inhibitor; Renal interstitial fibrosis; Signaling pathway.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no potential conflicts of interest.

Figures

Fig. 1
Fig. 1
Effects of HDACi and its associated signaling pathways in renal interstitial fibrosis. HDACi is showing to protect against interstitial fibrosis through multiple signaling pathway as indicated. EGF, epidermal growth factor; TGF, transforming growth factor; TGFR, TGF-receptor; HDACi, histone deacetylases inhibitor; STAT3, signal transducer and activator of transcription 3; α-SMA, α-smooth muscle actin.
See this image and copyright information in PMC

References

    1. Liu BC, Tang TT, Lv LL, Lan HY. Renal tubule injury: a driving force toward chronic kidney disease. Kidney Int. 2018 Mar;93((3)):568–79. - PubMed
    1. Lv W, Booz GW, Fan F, Wang Y, Roman RJ, Oxidative Stress and Renal Fibrosis Recent Insights for the Development of Novel Therapeutic Strategies. Front Physiol. 2018 Feb;16(9):105. - PMC - PubMed
    1. Nastase MV, Zeng-Brouwers J, Wygrecka M, Schaefer L. Targeting renal fibrosis: mechanisms and drug delivery systems. Adv Drug Deliv Rev. 2018 Apr;129:295–307. - PubMed
    1. Yang YM, Seki E. TNFα in liver fibrosis. Curr Pathobiol Rep. 2015 Dec;3((4)):253–61. - PMC - PubMed
    1. Klinkhammer BM, Floege J, Boor P. PDGF in organ fibrosis. Mol Aspects Med. 2018 Aug;62:44–62. - PubMed